Enterprise genomics company Helix announced on Tuesday a multi-year relationship with biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN).

Under this agreement AstraZeneca will gain access to Helix's continuously growing, deeply phenotyped GenoSphere cohorts that cover a wide range of disease areas.

Helix says that GenoSphere cohorts consist of comprehensive Exome+ genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. These de-identified datasets are powered by the Helix Research Network, a precision health network in North America.

"By combining comprehensive genomic data with rich longitudinal clinical information, we can help accelerate research, generate deeper insights into disease, and advance the development of more targeted medicines," said James Lu, M.D., Ph.D., CEO and co-founder of Helix.